[{"id":"ebc320e8-5c03-4ecc-88dc-a788f595b07f","acronym":"ALCAPONE","url":"https://clinicaltrials.gov/study/NCT02281214","created_at":"2021-01-18T10:44:37.756Z","updated_at":"2024-07-02T16:37:04.244Z","phase":"","brief_title":"NGS Genome Analysis in Personalisation of Lung Cancer Treatment","source_id_and_acronym":"NCT02281214 - ALCAPONE","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 10/24/2014","start_date":" 10/24/2014","primary_txt":" Primary completion: 11/17/2014","primary_completion_date":" 11/17/2014","study_txt":" Completion: 11/17/2018","study_completion_date":" 11/17/2018","last_update_posted":"2019-01-04"}]